|
| Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Bullion ~ Forex ~ Sports ~ Technology ~ Health ~ Features |
| Lung Cancer ~ Lung Cancer ~ Breast Cancer ~ Heart attack ~ All Health Topics |
|
Home
/ Health News / 2007 / October 2007 / October 10, 2007 Ultra-low-dose aspirin may reduce bleeding in portal hypertension patients |
How binge drinking drives heart disease
Lack of exercise put depressed heart patients at greater risk
How cancer prevention drives aging
For the first time, researchers have found how cellular senescence, the well-known mechanism for preventing cancer, can trigger aging and age-related disease by changing the local tissue environment. ANI
Scientists unveil genes vital to vital to adult heart function
In a study on fruit fly Drosophila, scientists at the Burnham Institute for Medical Research (Burnham) have found that genes involved in embryonic heart development are vital to adult heart function in both fruit flies and humans. ANI
Psychiatric disorders common among college-aged
A new study has revealed that psychiatric disorders appear to be common among 18- to 24-year-olds, with overall rates similar among those attending or not attending college. ANI
A new research in rats has shown that ultra-low-dose aspirin can decrease bleeding severity in patients with portal hypertension.
Washington, Oct 10 : A new research in rats has shown that ultra-low-dose aspirin can decrease bleeding severity in patients with portal hypertension.
The study led by Professor C. Doutremepuich, has shown a normalizing effect of platelet-endothelial cell alterations and bleeding time.
Further, this effect is mediated by Cyclooxygenase 2 inhibition.
Ultra-low-dose aspirin has a prothrombotic effect that is the opposite of that observed with usual doses for the prevention of stroke or heart attack. The antithrombotic properties of low-dose aspirin are achieved by the inhibition of COX 1 in platelets.
Aspirin is the most widely used antithrombotic agent. Prior studies in rats have shown that the prothrombotic properties of ultra-low-dose aspirin are not mediated by platelets but by endothelial cells, and as such they have the potential of reversing the platelet-endothelial cell interaction alterations observed in portal hypertension.
According to researchers, till date no clear explanation has existed to explain the effect of such a small dose of aspirin, and no mechanism has been found to explain this contradictory action.
The prothrombotic effects of COX 2 inhibitors became evident in 2004 when one of the most widely accepted non-steroidal anti-inflammatory drugs was withdrawn from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use. Only aspirin has been demonstrated to have a prothrombotic effect at a very low dose.
Portal hypertension is a major complication of chronic liver disease, and bleeding is one of its most severe problems, leading often to death. Currently no treatment is used to modify the altered platelet activity observed in this pathology.
The new research, is published in the October 14 issue of the World Journal of Gastroenterology.
ANI
